The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Regulatory News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

16 Feb 2022 11:47

RNS Number : 8892B
e-Therapeutics plc
16 February 2022
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00B2823H99

Issuer Name

E-THERAPEUTICS PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of financial instruments

3. Details of person subject to the notification obligation

Name

Spreadex LTD

City of registered office (if applicable)

St. Albans

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

14-Feb-2022

6. Date on which Issuer notified

16-Feb-2022

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

0.000000

< 3%

Position of previous notification (if applicable)

0.000000

4.005700

4.005700

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

Sub Total 8.A

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

CFD/Spreadbet

5168858

1.004500

Sub Total 8.B1

5168858

1.004500%

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

Matthew Allen01727895011

12. Date of Completion

16-Feb-2022

13. Place Of Completion

UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLEAFAKFLSAEFA
Date   Source Headline
31st May 20182:13 pmRNSResults of Annual General Meeting
1st May 20187:00 amRNSCollaboration with C4X Discovery Holdings PLC
4th Apr 20184:13 pmRNSNotice of AGM
27th Mar 20187:00 amRNSFull Year Results
12th Mar 20187:00 amRNSNotification of Full Year Results Date
22nd Jan 20187:00 amRNSDirector/PDMR Shareholding
15th Jan 20187:00 amRNSE-Therapeutics enters two AI collaborations
3rd Jan 20187:00 amRNSDirector/PDMR Shareholding
18th Dec 20172:31 pmRNSHolding(s) in Company
18th Dec 20178:57 amRNSDirector/PDMR Shareholding
1st Nov 20177:00 amRNSAppointment of Director
5th Oct 201711:35 amEQSEdison issues update on e-Therapeutics (ETX)
26th Sep 20177:00 amRNSInterim Results for 6 Months Ended 31 July 2017
5th Sep 20179:41 amRNSNotice of Results
22nd Aug 20172:13 pmRNSDirector/PDMR Shareholding
27th Jul 20174:46 pmRNSEdison issues update on e-Therapeutics (ETX)
27th Jul 20173:24 pmEQSEdison Investment Research Limited: Edison issues update on e-Therapeutics (ETX)
24th Jul 20177:00 amRNSOutcome of Strategic Review and Future Plans
3rd Jul 20174:50 pmRNSDirector/PDMR Shareholding
19th Jun 201710:13 amRNSTR-1: Notification of Major Interest in Shares
5th Jun 20172:21 pmRNSTR-1: Notification of Major Interest in Shares
2nd Jun 20173:19 pmRNSTR-1: Notification of Major Interest in Shares
2nd Jun 20172:50 pmRNSTR-1: Notification of Major Interest in Shares
2nd Jun 201712:02 pmRNSTR-1: Notification of Major Interest in Shares
2nd Jun 20179:00 amRNSDirector/PDMR Shareholding
31st May 20172:01 pmRNSResults of Annual General Meeting
25th May 201711:20 amRNSNotification by Director
23rd May 20174:22 pmRNSDirector/PDMR Shareholding
8th May 20173:02 pmRNSNotice of Annual General Meeting and Annual Report
3rd May 20179:00 amRNSDirector/PDMR Shareholding
19th Apr 20177:00 amRNSFinal Results
6th Apr 20177:01 amRNSNotification of Full Year Results Date
6th Apr 20177:00 amRNSNew CEO Commences at e-Therapeutics
4th Apr 20178:30 amRNSHolding(s) in Company
4th Apr 20178:30 amRNSHolding(s) in Company
16th Feb 20177:00 amRNSDirectorate Change
12th Jan 201710:38 amRNSHolding(s) in Company
9th Jan 20177:00 amRNSAppointment of CEO
4th Jan 20177:00 amRNSDirector/PDMR Shareholding
23rd Nov 20164:21 pmRNSGrant of share options and Directors' dealings
6th Oct 201610:12 amRNSDirectors' Dealings and Issue of Equity
3rd Oct 20162:03 pmRNSFurther re: Directors' Shareholdings
21st Sep 20164:06 pmRNSIssue of Equity and Directors' shareholdings
20th Sep 20167:00 amRNSHalf year results
14th Sep 201612:08 pmRNSManagement Update
9th Sep 20169:30 amRNSNotice of Half Year Results
18th Aug 20165:07 pmRNSHolding(s) in Company - Correction
18th Aug 201611:07 amRNSHolding(s) in Company
1st Aug 20164:40 pmRNSIssue of Equity
13th Jul 201610:05 amRNSBoard changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.